Bloodless surgery in gynecologic oncology

Mount Sinai Journal of Medicine

Volumn 76, Issue 6, 2009, Pages 589-597

  Nagarsheth, Nimesh P ^a,b   Sasan, Fahimeh ^a,b  

^a ENGLEWOOD HOSPITAL AND MEDICAL CENTER   (United States)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Anemia; Bloodless surgery; Cancer; Gynecology; Jehovah's Witness

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; IRON; NONSTEROID ANTIINFLAMMATORY AGENT; RECOMBINANT ERYTHROPOIETIN;

ALLOTRANSPLANTATION; BLOOD AUTOTRANSFUSION; BLOOD TRANSFUSION; BLOODLESS SURGERY; CLINICAL PRACTICE; DISEASE TRANSMISSION; DRUG EFFICACY; DRUG SAFETY; DYSPNEA; FEVER; GYNECOLOGIC CANCER; HEPATITIS B; HEPATITIS C; HUMAN; HYPOTENSION; IMMUNIZATION; IMMUNOMODULATION; INTENSIVE CARE UNIT; ONCOLOGY; PHLEBOTOMY; POSTOPERATIVE PERIOD; PREOPERATIVE PERIOD; RELIGION; REVIEW; RISK ASSESSMENT; SURGICAL TECHNIQUE; TRANSFUSION RELATED ACUTE LUNG INJURY;

BLOOD LOSS, SURGICAL; FEMALE; GENITAL NEOPLASMS, FEMALE; GYNECOLOGIC SURGICAL PROCEDURES; HUMANS; INTRAOPERATIVE CARE; JEHOVAH'S WITNESSES; POSTOPERATIVE CARE; PREOPERATIVE CARE; SURGICAL PROCEDURES, MINIMALLY INVASIVE;

EID: 73349105882     PISSN: 00272507     EISSN: 19317581     Source Type: Journal    
DOI: 10.1002/msj.20146     Document Type: Review

References (38)

1. Nagarsheth NP, Shander A, Malovany R, et al. Bloodless surgery in a Jehovah's Witness patient with a 12.7-kg uterine leiomyosarcoma. J Surg Educ 2007; 64: 212-219.
2. Goodnough LT, Shander A, Spence R. Bloodless medicine: clinical care without allogeneic blood transfusion. Transfusion 2003; 43: 668-676.
3. DeCastro R. Bloodless surgery: establishment of a program for the special medical needs of the Jehovah's Witness community-the gynecologic surgery experience at a community hospital. Am J Obstet Gynecol 1999; 180: 1491-1498.
4. Hardy JF. Current status of transfusion triggers for red blood cell concentrates. Transfus Apher Sci 2004; 31: 55-66.
5. Hajjar LA, Auler Junior JO, Santos L, Galas F. Blood transfusion in critically ill patients: state of the art. Clinics 2007; 62: 507-524.
6. Friedman BA, Burns TL, Schork MA. A study of blood utilization by diagnosis, month of transfusion, and geographic region of the United States. Transfusion 1979; 19: 511-525.
7. American Association of Blood Banks. Transfusiontransmitted diseases, April 2007. Available at: http:// www.aabb.org. Accessed September 2009.
8. Taylor RW, Manganaro L, O'Brien J, et al. Impact of allogeneic packed red blood cell transfusion on nosocomial infection rates in the critically ill patient. Crit Care Med 2002; 30: 2249-2254.
9. Chelemer SB, Prato BS, Cox PM, et al. Association of bacterial infection and red blood cell transfusion after coronary artery bypass surgery. Ann Thorac Surg 2002; 73: 138-142.
10. Hansen E, Kneuchel R, Altmeppen J, Taeger K. Blood irradiation for intraoperative autotransfusion in cancer surgery: demonstration of efficient elimination of contaminating tumor cells. Transfusion 1999; 39: 608-615.
11. Blumberg N. Allogeneic transfusion and infection: economic and clinical implications. Semin Hematol 1997; 34: 34-40.
12. Klein, H. Immunomodularity aspects of transfusion: a once and future risk? Anesthesiology 1999; 91: 861-865.
13. McAlister F, Clark H, Wells P, Laupacis A. Perioperative allogeneic blood transfusion does not cause adverse sequelae in patients with cancer: a meta-analysis of unconfounded studies. Br J Surg 1998; 85: 171-178.
14. Shander A, Popovsky, MA. Understanding the consequences of transfusion-related acute lung injury. Chest 2005; 128: 598s-604s.
15. Toy P, Popovsky MA, Abraham E, et al. Transfusionrelated acute lung injury: definition and review. Crit Care Med 2005; 33: 721-726.
16. Sachs UJ. The pathogenesis of transfusion-related acute lung injury and how to avoid this serious adverse reaction of transfusion. Transfus Apher Sci 2007; 37: 273-282.
17. Popovsky MA, Chaplan HC, Moore SB. Transfusion-related lung injury: a neglected serious complication of hemotherapy. Transfusion 1992; 32: 589-592.
18. Popovsky MA. Transfusion-related acute lung injury: incidence, pathogenesis and the role of multicomponent apheresis in its prevention. Transfus Med Hemother 2008; 35: 76-79.
19. Nagarsheth NP, Gupta N, Moshier E, et al. Responses on advance directives by Jehovah's Witnesses on a gynecologic oncology service. Abstracts presented for the 39th annual meeting of the Society of Gynecologic Oncologists. Gynecol Oncol 2007; 108: s1-s182.
20. Smoller BR, Kruskall MS. Phlebotomy for diagnostic laboratory tests in adults: pattern of use and effect on transfusion requirements. N Engl J Med 1986; 314: 1233-1235.
21. Beris P, Munoz M, Garcia-Erce A, et al. Perioperative anaemia management: consensus statement on the role of intravenous iron. Br J Anaesth 2008; 100: 599-604.
22. Procrit (epoetin alfa) prescribing information. Available at: http://www.procrit.com/procrit/shared/OBI/PI/ ProcritBooklet.pdf#page=1. Accessed September 2009.
23. Horowitz NS, Gibb RK, Menegakis NE, et al. Utility and cost effectiveness of preoperative autologous blood donation in a university-based gynecologic oncology practice. Gynecol Oncol 2004; 92: 1-512.
24. ́Elias D, Vaĺerie, Vaĺerie L. Use of the cell saver in oncologic surgery. Transfusion alternatives. Transfus Med 2008; 3: 25-28.
25. Heiss MM, Mempel W, Jauch KW, et al. Beneficial effects of autologous blood transfusion on infectious complications after colorectal cancer surgery. Lancet 1993; 342: 1328-1333.
26. Jarnagin WR. A prospective randomized trial of acute normovolemic hemodilution compared to standard intraoperative management in patients undergoing major hepatic resection. Ann Surg 2008; 248: 360-369.
27. Santoso JT, Hannigan EV, Levine L, et al. Effect of hemodilution on tissue perfusion and blood coagulation during radical hysterectomy. Gynecol Oncol 2001; 82: 252-256.
28. Shander A, Goodnough L. Objectives and limitations of bloodless medical care. Curr Opin Hematol 2006; 13: 462-470.
29. Munoz M, Breymann C, Garcia-Erce JA, et al. Efficacy and safety of intravenous iron therapy as an alternative/adjunct to allogeneic blood. Vox Sang 2008; 94: 172-183.
30. Madjdpour C, Donat S, Richard B. Anemia and perioperative red blood cell transfusion: a matter of tolerance. Crit Care Med 2006; 34: s102-s108.
31. Shander A. Surgery without blood. Crit Care Med 2003; 31: s709-s714.
32. Stovall TG. Clinical experience with epoetin alfa in the management of hemoglobin levels in orthopedic surgery and cancer: implications for use in gynecologic surgery. J Reprod Med 2001; 46: 531-538.
33. Suzuki Y, Tokuda Y, Fujiwara Y, et al. Weekly epoetin beta maintains haemoglobin levels and improves quality of life in patients with non-myeloid malignancies receiving chemotherapy. Jpn J Clin Oncol 2008; 38: 214-221.
34. Rizzo JD, Somerfield MR, Hagerty KL, et al. Use of epoetin and darbopoetin in patients with cancer: 2007 American Society of Clinical Oncology/American Society of Hematology clinical practice guideline update. J Clin Oncol 2008; 26: 132-149.
35. Juneja V, Keegan P, Gootenberg JE, et al. Continuing reassessment of the risks of erythropoiesis-stimulating agents in patients with cancer. Clin Cancer Res 2008; 14: 3242-3247.
36. Nagarsheth NP, Gupta A, Gretz HF, et al. Feasibility of bloodless surgery on a gynecologic oncology service. Int J Gynecol Cancer 2006; 16: 624-694.
37. Epogen (epoetin alfa): FDA complete response and safety labeling change order: July 30, 2008. Available at: http://www.accessdata.fda.gov/drugsatfda docs/label/ 2008/103234s5195sPI.pdf. Accessed September 2009.
38. Nagarsheth, NP, Sharma T, Shander A, Awan A. Blood salvage use in gynecologic oncology. Transfusion. doi://10.1111/j.1537-2995.2009.02256. x. Available at: http://www3.interscience.wiley.com.